Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Generics Showed Strong Growth in 1st Half of FY2013 Despite Lack of New Measures to Promote Their Use
December 6, 2013
- Kyowa Kirin Shutters Yokkaichi Plant
December 6, 2013
- M3 to Make Mediscience Planning Its Wholly Owned Subsidiary
December 6, 2013
- Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated
December 5, 2013
- Takeda to Market Teva’s Multiple Sclerosis Treatment in Japan
December 5, 2013
- Sawai President Requests Cautious Discussions on Generic Prices, Shows Confidence in Surviving
December 5, 2013
- “Big Gap” Remains to Reach 5-Year Profit Target: Astellas Pres.
December 5, 2013
- DSP, Healios Tie Up, Aim to Launch iPS Products in 2018
December 4, 2013
- Ono Joins SGLT-2 Inhibitor Battle via Copromotion Deal with AstraZeneca
December 4, 2013
- Eisai Shakes Up R&D Organization, Paring 130 Jobs in US, Europe
December 4, 2013
- Eisai to Transfer Business Operations at Misato Plant to Bushu Pharmaceuticals
December 4, 2013
- Bayer HealthCare Files Eylea for mCNV in Japan
December 4, 2013
- Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later
December 3, 2013
- Takeda Ready to Welcome Foreign Exec with Open Arms as Company Leader
December 3, 2013
- Japan Gardasil Sales Dive 49.6% in January-September
December 3, 2013
- Merck to Shed 200 Jobs in Japan by 2015
December 3, 2013
- Eisai to Offer Voluntary Retirement Program in Japan
December 3, 2013
- Takeda President Calls GSK Weber Competitive Global Talent, Pushes Globalization
December 2, 2013
- Eisai Files for Approval of Pariet for Preventing Recurrent Ulcers during Aspirin Therapy
December 2, 2013
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…